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Abstract.  Fibroblast growth factor (FGF) and type/3 
transforming  growth factor ('rGF/3)  are potent modula- 
tors of proliferation and differentiation in many types 
of cells. TGF/~ acts in an autocrine manner,  and the 
regulation of TGF/3 gene expression is one of the cru- 
cial events in the control of cellular functions.  This 
study examines FGF regulation of TGF/31 gene expres- 
sion in osteoblast-like cells. Bovine basic FGF (bFGF) 
increased the steady-state level of 2.5-kb TGF/31 
mRNA two- to threefold in rat osteosarcoma 
(ROS17/2.8)  cells in a dose-dependent manner,  starting 
at 0.1  ng/ml.  The increase of the message was detect- 
able within 3 h after the addition of bFGF, peaked at 
6 h,  and lasted at least up to 48 h.  This effect was 
blocked by a protein kinase inhibitor,  K252a,  indicat- 
ing the involvement of phosphorylation,  bFGF in- 
creased the rate of TGF/31 gene transcription  estimated 
by nuclear run-on assay,  while the stability of TGF/31 
mRNA was not altered,  bFGF increased the TGF/3 ac- 
tivity in the conditioned media,  estimated by DNA 
synthesis inhibition assay using mink lung epithelial 
(CCL-64) cells. Parathyroid hormone reduced the 
abundance of TGF/31 mRNA in ROS17/2.8  cells and 
opposed the bFGF effect on TGF/31 mRNA. bFGF 
also increased the steady-state level of TGF/31 mRNA 
in mouse calvaria-derived MC3T3E1  and human os- 
teosarcoma SaOS-2 cells. These findings indicate that 
FGF enhances the expression of TGF/31 gene in 
osteoblast-like cells and point to the tight relationship 
of the two growth factors involved in the control of 
cellular functions. 
F 
IBROBLAST growth factor (FGF)'  and type /3 trans- 
forming growth factor (TGFB) are potent modulators 
of proliferation  and differentiation  in a wide variety 
of cells (Gostxxlarowicz et al., 1987a, Thomas and Gimenez- 
Gallego,  1986; Thomas, 1987, 1988; Massague, 1985, 1987; 
Sporn et al., 1986, 1987). FGF and TGF/3 coordinately regu- 
late the extracellular  matrix accumulation and are implicated 
in tissue repair, angiogenesis, and early embryogenesis (Slack 
et al., 1987; Gospodarowicz et al., 1987a,b; Kimelman  and 
Kirschner,  1987; Weeks  and  Melton,  1987; Schweigerer, 
1988). On the other hand,  the two growth factors counteract 
each other in certain  cases, such as the regulation  of plas- 
minogen activator activity (Saksela et al., 1987; Gospodaro- 
wicz et al., 1987a,b). The diverse directions  of their interac- 
tion appear to be due to the bifunctional  nature  of TGF/~ 
(Roberts et al., 1985; Sporn et al., 1986, 1987; Centrella et 
al.,  1987a). These features of the two growth factors reveal 
their close relationship  in modulation of cell functions, espe- 
cially proliferation  and extracellular  matrix accumulation. 
TGFB and FGF are relatively abundant in bone (Hauschka 
et al., 1986; Seyedin et al., 1985, 1986) where they are pro- 
1. Abbreviations  used in this paper: bFGF, basic fibroblast growth factor; 
DRB, 5,6-dichloro-1-/3-D-ribofuranosylbenzimidazole;  FGF, fibroblast growth 
factor; PTH, parathyroid hormone; TGF/~, type/3 transforming growth factor. 
duced by osteoblasts (Globus et al.,  1989;  Robey et al., 
1987).  In osteoblast-rich  cultures  or osteoblast-like  cells, 
FGF stimulates  proliferation  and expression of osteocalcin 
(in bovine cells) and osteopontin, while it inhibits the expres- 
sion of alkaline  phosphatase,  collagen,  osteocalcin (in rat 
cells), and parathyroid hormone (PTH)-responsive adenylate 
cyclase activity (Canalis  and Raisz,  1980;  Canalis,  1980, 
1985; Guenther et al.,  1986; Canalis et al.,  1987, 1988a,b; 
Globus et al.,  1988; Rodan et al.,  1987, 1989; Centrella  et 
al.,  1987b).  TGF#, on the other hand,  either stimulates  or 
inhibits proliferation and expression of  alkaline phosphatase; 
enhances expression of collagen, osteonectin, and osteopon- 
tin genes; and inhibits osteocalcin gene expression in osteo- 
blast-like  cells (Centrella  et al.,  1986, 1987a,b;  Noda and 
Rodan,  1986, 1987; Pfeilshifter  et al.,  1987; Globus et al., 
1988; Noda et al.,  1988a;  Noda,  1989).  In addition,  high 
doses of TGF/31 and TGF/T2 stimulate periosteal bone forma- 
tion in vivo (Noda and Camilliere,  1989). Thus,  both FGF 
and TGF/3 potently modulate the functions of osteoblasts in 
an autocrine manner. 
Regulation of the expression  of TGF/3 gene is one of the 
crucial events in the control of cellular function by this auto- 
crine factor. TGF/$1 expression is stimulated  by TGF/31 it- 
self, EGF, PDGF (Schilling  et al.,  1988),  and tumor pro- 
moter  12-tetradecanoyl-phorbol-13  acetate  (Akhurst  et al., 
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lated developmentally (Gospodarowicz et al., 1987a,b; Sporn 
et al.,  1986,  1987).  We examined the FGF regulation of 
TGF~ gene expression and found that FGF enhances the ex- 
pression of TGF~  gene in rat,  mouse, and human osteo- 
blast-like cells. 
Materials and Methods 
Bovine brain-derived basic FGF (bFGF) and acidic FGF, porcine platelet- 
derived "IGFfll, and neutralizing antibody against TGFfl were purchased from 
R & D Systems, Inc. (Minneapolis, MN). Recombinant bFGF and synthetic 
human PTH (1-34) were obtained from Bachem Inc. (Torrance, CA). [c~- 
32p]dCTP  (3,000  Ci/mmol) and  [c~-32pIUTP (800  Ci/mmol)  were pur- 
chased from Amersham Corp. (Arlington Heights, IL). A simian TGFfll 
cDNA (Sharpies et al.,  1987)  was kindly provided by Dr.  Purchio (On- 
cogene Science, Inc., Seattle, WA). 
Cell Culture 
ROS17/2.8 cells were grown in 9.5- or 150-cm  2 Costar (Cambridge, MA) 
or Nunc (Roskilde, Denmark) tissue culture dishes in modified Ham's FI2 
medium supplemented with 5 % FBS and 100/~g/ml kanam2~in as described 
previously (Noda and Rodan, 1987).  MC3T3EI cells were kindly provided 
by Dr. Kodama (Oh-u University, Fukushima, Japan) and were maintained 
as described previously in a-minimum essential medium supplemented 
with 60 tzg/ml kanamycin and 10% FBS (Sudo et ai.,  1983).  SaOS2 cells 
were obtained from American Type Culture Collection (Rockville, MD) 
and were cultured in RPMI-1640 media supplemented with 1% glutamine, 
100 t~g/ml kanamycin, and  10%  FBS. 
RNA Isolation 
ROS17/2.8,  MC3T3EI,  or SaOS2 cells were grown to confluence in  150- 
cm  2 dishes and were treated for an indicated period of time with bFGF or 
other agents.  Cytoplasmic RNA  was  extracted as described previously 
(Greenberg and Ziff,  1984;  Noda and Rodan,  1987).  Cells (1-3  x  107) 
were rinsed with cold PBS, scraped in PBS, and centrifuged at 500 g at 4"C. 
The cell pellets were resnspanded in I ml of NP-40 lysis buffer (10 mM Tris- 
HCI,  pH 7.4,  10 mM NaCI,  3  mM MgCI2,  0.5%  [vol/vol]  NP-40),  in- 
cubated on ice for 5 min, and then spun at 500 g at 4°C for 2 rain. The 
supernatants were mixed with vanadyl ribonucleoside complex (final con- 
centration 10 mM), vortexed, and spun at 12,000 g at 40C for 10 min. The 
supernatants were mixed with equal volume of digestion buffer (0.2 M Tris- 
HCI, pH 7.4, 0.44 M NaCI, 2 % SDS, 25 mM EDTA) containing proteinase 
K (final concentration 200 t~g/mi), incubated at 37°C for 60-120 min, phe- 
nol/chloroform (1:1) extracted, and ethanol precipitated. RNA was quanti- 
tated by spectrometry at the wavelength of 260 urn. 
Northern Blot Analysis 
Total  cytoplasmic RNA  (10  or 20  /~g) was  subjected to electrophoresis 
through  1%  agarose-formaidehyde (0.44  M)  gel and  electrophoretically 
transferred to nylon filters (Hybond N; Amersham Corp.) (Thomas, 1980). 
Complementary DNA probes for simian TGF31 (Sharpies et al., 1987) and 
rat fl-actin (LK 280)  were digested to liberate inserts. The inserts were 
purified and labeled with [~-32P]dCTP by using random oligonucleotide 
primers (Amersham Corp.) and Klenow fragment as described by Feinberg 
and Vogelstein (1984) to a specific activity >10  s cpm//~g.  Membranes with 
bound RNA were irradiated for 2 rain by ultraviolet light to cross-link the 
RNA to the filters. Then the filters were prehybridized overnight at 42°C 
in 50% formamide, 5× SSC (1× SSC =  0.15 M NaCI, 15 mM sodium ci- 
trate), 5× Denhardt's solution, 0.1% SDS, and 200 ttg/ml sonicated herring 
sperm DNA. Hybridization was carried out for 16-24 h in fresh prehybrid- 
ization buffer to which each 32p-labeled  probe was added at  106 cpm/ml. 
Filters were washed three times in 2× SSC, 0.1% SDS at room temperature 
for 5 min each, washed once in 0.1% SDS, 0.1×  SSC at 65°C for 30 min, 
and exposed to x-ray films (Eastman Kodak Co., Rochester, NY) with inten- 
sifying screens. 
In Vitro Nuclear Transcription (Nuclear Run-on) 
Assay 
Isolation of  nuclei, in vitro transcription, and hybridization were carried out 
essentially as described previously (McKnight and Palmiter,  1979;  Grou- 
dine et al.,  1981; Harrison et al.,  1989) with minor modifications (Noda 
et al.,  1988a;  Noda,  1989).  Nuclei (2-3  x  107) were isolated by gentle 
homogenization of cells on ice in a buffer containing 10 mM KCI, 10 mM 
Tris-HCl, pH 7.4,  1.5 mM MgCI2, 0.25%  (vol/vol) NP-40.  The isolated 
nuclei were incubated at 25°C for 20 rain in a buffer containing 50 mM Tris- 
HCI, pH 7.4;  100 mM ammonium sulfate; 1.8 raM DTT;  1.8 mM MnCI2; 
80  U  RNasin; 0.3  mM each ATE GTP,  and CTP;  and  100/~Ci  of [c~- 
32p]UTP  (800 Ci/mmol; Amersham Corp.) followed by sequential diges- 
tions with DNase I and proteinase K. RNA was extracted by phenol/chloro- 
form and was precipitated in ethanol. After centrifugation at 12,000 g for 
10 min, the pellets were dissolved in 6 M guanidium hydrochioride followed 
by addition of 0.5 vol ethanol and were reprecipitated at -20°C overnight. 
After centrifugation at 12,000 g for 10 rain at 4°C, the pallets were rinsed 
with cold 80% ethanol, dried, and resuspended in TE buffer (10 mM Tris- 
HCI, pH 7.4,  1 mM EDTA). Isolated 32p-labeled transcripts (final concen- 
tration 2-3  x  106 cpm/rnl) were hybridized to plasmids (2/~g each) bound 
to nitrocellulose filter.  Prehybridization (12-16 h) and hybridization (72 h) 
were carried out in 5×  SSC, 50% formamide, 5×  Denhardt's solution, 10 
mM EDTA,  100 mM Tris-HCl, pH 7.4,  20 ~g/ml tRNA,  10 ttg/ml poly- 
adenylic acid,  10 ~tg/ml sonicated herring sperm DNA, and 0.1% SDS at 
42°C. Filters were washed three times in 2× SSC, 0.1% SDS at room tem- 
perature for 5 min each and once in 0.2×  SSC, 0.1% SDS at 60°C for 15 
rain. The filters were then autoradiographed at  -70°C using intensifying 
screens. Quantitation of  the signals was carried out by densitometric scanning. 
Mink Lung Epithelial (CCL-64) Cell Assay 
Mink lung epithelial (CCL-64) cells were kindly provided by Dr. Weather- 
bee (R & D Systems) and were maintained in DME supplemented with 10% 
FBS. DNA synthesis inhibition assay was carried out as described by Daniel- 
pour et al. (1989) with minor modification. Briefly, CCL-64 cells in loga- 
rithmic growth phase were trypsinized, resuspended in 10% FBS, washed 
once with assay medium (DME supplemented with 0.2% FBS), resuspended 
again in assay medium, plated at 8  x  104 cells/100 #1 in 0.32-cm  2 wells 
(96-well plate; Costar), and cultured for 2 h. After aliquots (50 #1) of condi- 
tioned media corresponding to the same number of the ROS cells (prepared 
as described below) were added, CCL-64 cells were cultured overnight 
(16-20 h) followed by pulse-labeling with [3H]thymidine (6.7 Ci/mmol; 
New England Nuclear, Boston, MA) at final concentration of I #Ci/ml for 
2 h. The cells were fixed with 100 #i of methanol/acetic acid (3:1 [voi/vol]) 
and were washed three times with 80% methanol. 3H-Labeled DNA was 
extracted by a 30-min treatment with 100 #1 0.5% trypsin followed by the 
addition of 100 #12% SDS. Radioactivity was measured by a liquid scintil- 
lation counter.  The statistical  significance of the data was evaluated by t test. 
Preparation of Conditioned Medium 
Confluent ROS17/2.8 cells in 9.5-cm  2 dishes were rinsed three times with 
PBS, cultured in 1 ml serum-free F12 medium overnight in the absence or 
the presence of 1 ng/ml bFGE rinsed three times with PBS, and cultured 
in 1 ml assay medium for 20 h with or without 1 ng/ml bFGE A part of 
media prepared with or without 1 ng/ml bFGF was kept at 4°C and was used 
as  unconditioned media.  The  cells were trypsinized and  counted by  a 
counter (Coulter Electronics Inc., Hialeah, FL), and the conditioned media 
were harvested and centrifuged at 12,000 g for 5 rain at 4°C to remove cell 
debris. Supernatant was transferred to a new tube and was heated at 95°C 
for 5 min before the addition to CCL-64 cell culture. 
Results 
Bovine bFGF (10 ng/ml) increased the steady-slate level of 
TGFfll mRNA two- to threefold after 48 h in rat osteoblastic 
osteosarcoma (ROS17/2.8)  cells (Fig.  1 A). This effect was 
observed within 3 h after the addition of bFGF (Fig.  1 B) 
and lasted at least up to 48 h (Fig. 1 C). ~Actin mRNA levels 
on the same Northern filters served as control (Fig. 1, B and 
C). The similar levels of these fl-actin mRNA in control and 
FGF-treated cultures indicated that the observed increase of 
TGF~  mRNA  was  not due to the changes in poly-A  + or 
ribosomal RNA fractions. The abundance of TGF~I mRNA 
relative to actin  mRNA  was  calculated as Ac (or Af)  = 
TGF31/actin, where Ac and Af represent control and FGF- 
The Journal  of Cell Biology,  Volume 109, 1989  2530 Figure 2. Dose response of  the bFGF effect on the steady-state level 
of TGF/~I mRNA. Confluent ROS17/2.8 ceils were treated with in- 
dicated doses of bFGF for 36 h. Cytoplasmic RNA was isolated as 
described in Materials and Methods and was used for Northern blot 
hybridization to 32P-labeled probe.  The position of TGFBI and 
18S ribosomal RNA are indicated.  (A) Dose dependence of bFGF 
effects on TGFB1 mRNA level. (B) Quantitation  of TGFBI mRNA 
bands in A. The relationship  between the relative magnitude of the 
response (Y) and dose (X) fits the equation,  Y =  1.46 x  logt0X + 
6.76, in which the regression coefficient was statistically  significant 
(p <  0.05) as judged by F test.  The figures represent  one of three 
similar experiments. 
Figure 1. Time course ofbFGF effect on TGFBI mRNA. Confluent 
ROS17/2.8 cells were cultured for 48 h  (A) or for the  indicated 
periods of time in hours in the absence (lanes  C) or the presence 
(lanes F) of 10 ng/mi bFGF (B and C). Cytoplasmic RNA was iso- 
lated as described in Materials  and Methods, and 10 #g was loaded 
on each lane for Northern blot hybridization to 32p-labeled TGFBI 
probe.  The same filters were rehybridized with 32p-labeled B-actin 
probe later.  The positions  of TGFBI,/~-actin (AC), and 18S ribo- 
somal RNA are indicated.  (B) Early time course of bFGF effect on 
TGF/~ 1 mRNA level. (C) Effect of prolonged treatment with bFGF 
on "rGF/31 mRNA level.  The figures represent one of two similar 
experiments. 
4 A). The apparent half-life of TGFIS1 mRNA, estimated by 
analyzing the decay of the message level after the treatment 
with DRB, was •6  h and was not altered by bFGF (Fig. 4 
B).  bFGF increased two- to threefold the rate of the tran- 
scription of TGFB1 gene, estimated by nuclear run-on assay 
(Fig. 5). The rate of the/~-actin gene transcription served as 
control and was not altered by the treatment with bFGE 
treated cultures,  respectively.  The ratios of Af/Ac at time 3, 
6, 10, 24, and 48 h in Fig. 1, B and C, were 1.3,  1.6, 2.1,  1.6, 
and  2.4,  respectively.  Bovine  acidic  FGF  also  increased 
TGFB1 mRNA level to a similar extent (data not shown). The 
effect of bFGF on the increase of TGFB1 mRNA after 36 h 
of treatment was dose dependent,  starting at 0.1 ng/ml (Fig. 
2, A  and B). 
The bFGF effect on TGF/~I mRNA was blocked by a pro- 
tein kinase inhibitor,  K252a,  suggesting the involvement of 
phosphorylation in mediation of the bFGF effect (Fig.  3). 
The bFGF effect was also blocked by a transcription inhibitor, 
5,6-dichloro-l~D-ribofuranosylbenzimidazole  (DRB)  (Fig. 
Figure  3.  Effect  of K252a  on  bFGF-induced  accumulation  of 
TGFB1 mRNA levels. Confluent ROS17/2.8 cells were treated with 
vehicle (lane C), 10 ng/ml bFGF (lane F), 1 ttM K252a (lane K), 
or bFGF and K252a (lane KF). After 10 h, cytoplasmic RNA was 
extracted and subjected to Northern blot analysis (10 ttg/lane) as de- 
scribed in Materials  and Methods. The positions of TGF/~I, B-actin 
(AC), and 18S ribosomal RNA are indicated.  The figure represents 
one of two similar  experiments. 
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in a 50-#1 aliquot (,x,30% inhibition) (Fig. 6 C). bFGF itself 
in  unconditioned  media did  not  inhibit  DNA synthesis  in 
CCL-64 cells (Fig. 6 A). Similar results were also obtained 
by colony formation assay in soft agarose using NRK-49F 
cells (data not shown). 
PTH acts as a  calcitropic agent in bone metabolism and 
opposes TGFB action on the expression of several pheno- 
typic genes in osteoblast-like ceils (Noda et al., 1988b; Noda 
and Rodan,  1989). 48 h of treatment with PTH reduced the 
TGF31 mRNA level (Fig. 7 A) and opposed the bFGF effect 
when added together (Fig.  7 B). 
Treatment with bovine bFGF for 48 h also increased the 
steady-state level of TGFB1  mRNA in  normal mouse cal- 
varia-derived MC3T3E1 cells and in human osteoblastic os- 
teosarcoma-derived SaOS2  cells  (Fig.  8),  suggesting  the 
generality of the bFGF effects on TGF/~I gene expression in 
osteoblastic cells. 
Figure 4. Effect of DRB on bFGF-induced TGF31 mRNA accumu- 
lation.  (A) Confluent  ROS17/2.8 cells  were treated  with  vehicle 
(lane  C),  10 ng/ml bFGF (lane F), 25 #g/ml DRB (lane R), or 
bFGF and DRB (lane RF). After 10 h, cytoplasmic RNA was iso- 
lated and was used for Northern blot analysis as described in Mater- 
ials and Methods. The positions of TGFBI, 3-actin (AC), and 18S 
ribosomal RNA are indicated. (B) Confluent ROS17/2.8 cells were 
treated with 25/zg/ml DRB for 5 and 10 h in the absence (control; 
open circle) or the presence of 10 ng/ml bFGF (solid circle).  The 
amount of TGF31 mRNA level was analyzed by Northern analysis 
as described in Materials and Methods.  Density of bands on auto- 
radiograms was quantitated by densitometry. The two decay curves 
(control and FGF-treated cultures) are parallel as  judged by parallel 
line assay (p < 0.05; Ftest). The figures represent one of  two similar 
experiments. 
To examine whether these bFGF effects on TGFB1 mRNA 
lead to the secretion of TGFBI protein, the amount of TGF3 
in  the  conditioned  media of these  cells  was estimated  by 
DNA synthesis inhibition assay using mink lung epithelial 
(CCL-64) cells. As shown in Fig. 6 A, conditioned media (50 
t~l) of ROS 17/2.8 ceils without treatment with FGF inhibited 
DNA synthesis in CCL-64 cells by 10-20% compared with 
unconditioned control media. Conditioned (50/A) media of 
the cells treated with bFGF (1 ng/ml) inhibited the DNA syn- 
thesis by  ~30%  compared with the conditioned  media of 
control ROS cultures.  This inhibition of DNA synthesis in 
mink lung (CCL-64) cells by FGF-conditioned media was 
blocked by neutralizing  antibody against TGF/~, indicating 
that the inhibitory activity in the conditioned media that was 
increased by FGF was attributed to TGFfl (Fig. 6 B).  The 
inhibitory activity in the conditioned media from ROS cell 
cultures treated with bFGF (at 1 ng/ml for 20 h) was close 
Discussion 
The results from this study show that FGF enhances the ex- 
pression of the TGFB1 gene. Both FGF and TGF~I are found 
in a wide variety of tissues and act coordinately or counteract 
each other's effects in  modulation of the function of many 
cells.  FGF stimulation of the TGF~I gene expression may 
confer either a positive or negative feedback mechanism in 
regulation of cellular functions.  In bone, both TGFEI and 
FGF are secreted by osteoblasts (Robey et al.,  1987; Globus 
et al.,  1988),  deposited  in bone matrix (Hauschka et al., 
1986; Globus et al.,  1989), and potently regulate bone cell 
function.  The accumulated FGF in bone matrix appears to 
1.0 
.6 
< 
u.  .4 
Control  b FGF 
p<O.05 
Figure 5. bFGF stimulation of TGF31 gene transcription.  Conflu- 
ent ROS1712.8 cells were cultured  for 24 h in the absence or the 
presence of 10 ng/ml bFGF. In vitro nuclear run-on assay was con- 
ducted as described  in Materials  and Methods.  The signals were 
quantitated by densitometry. The ratio (R) of TGFBI to actin was 
calculated by the following equation:  R  =  (TGF/~l-background)/ 
(actin-background). Plasmid vector (blue scribe) without insert was 
used to estimate background level, which was virtually zero. The 
rate of transcription of 3-actin gene was not altered by bFGF treat- 
ment. The significance of  the difference was evaluated by t test. The 
data are from 10 control and 11 FGF-treated cultures in a pool of 
four separate experiments and are expressed as mean  +  standard 
error. 
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mRNA.  (A) Confluent ROS17/2.8  cells were treated with vehicle 
(lane C)  or  10  -7 M  human  PTH  (1-34)  (lane P)  for 48  h.  (B) 
Confluent ROS17/2.8 cells were treated with vehicle (lane C),  10 
ng/ml bFGF (lane F),  10  -7 M  human  PTH  (1-34) (lane P),  or 
bFGF and PTH (lane PF) for 48 h. Cytoplasmic RNA was extracted 
and was used for Northern blot analysis as described in Materials 
and  Methods.  The  positions of TGF/31, ~actin  (AC),  and  18S 
ribosomal RNA are indicated. The figures represent one of two 
similar experiments. 
be stored in an active form (Globus et al., 1989) while most 
of  the  secreted  TFGI31  is  accumulated  in  a  latent  form 
(Pircher et al.,  1986;  Nakamura et al.,  1986;  Wakefield et 
al., 1988; Miyazono et al., 1988). It is still to be determined 
how the latent TGF/31 is activated after FGF enhancement of 
TGF/31 expression and accumulation in extracellular matrix. 
In vitro nuclear run-on assays indicated that FGF stimu- 
Figure 6. Increase of the TGF/3 activity in conditioned medium of 
ROS17/2.8 cells by treatment with bFGE Confluent ROS17/2.8 cells 
were cultured in the presence or the absence of I ng/ml bFGF. Prep- 
aration of the conditioned media and mink lung epithelial (CCL- 
64)  cell  assay were  carried out  as  described in  Materials and 
Methods. The numbers of ROS 17/2.8 cells after culture in the ab- 
sence or the presence of bFGF were 927,000  +  39,000  (mean  + 
standard error) and 936,000  +  43,000  cells per well, respectively. 
(A)  Unconditioned media or conditioned media were  heated  at 
95°C for 5 min and cooled before the addition to CCL-64 cell cul- 
tures in an aliquot of 50 t~l, which corresponds to 46,000 ROS cells. 
(B) Conditioned media were incubated with 200 #g/ml neutralizing 
antibody against TGF/3 for 1 h before the addition to CCL-64 cells 
(thick columns). The neutralizing antibody at the same concentra- 
tion completely blocked the inhibitory activity of purified TGF/31 
at 1 ng/ml. The antibody by itself did not affect the DNA synthesis 
in CCL-64 cells (thin columns).  (C) TGF/31 at the indicated con- 
centrations in a 50-~1 aliquot of assay media was added to CCL-64 
cell cultures (thin columns).  Thick columns indicate the effects of 
conditioned media. Triplicate wells were used for each condition. 
The data are expressed as mean +  standard error and represent the 
results from one of three similar experiments. The significance of 
the difference was evaluated by t test. (*) p <  0.05 against control. 
NS, no significant difference. 
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mRNA in murine calvaria-derived MC3T3E1 and human osteosar- 
coma SaOS2 cells. Confluent MC3T3E1 and SaOS2 cells were 
treated with either vehicle (lanes C) or 10 ng/ml  bFGF (lanes F) 
for 48 h. Cytoplasmic RNA was isolated and used for Northern 
analysis as described in Materials and Methods. The positions for 
TGFB1 and 18S ribosomal RNA are indicated. The figure  represents 
one of two similar experiments. 
lates TGFBI  gene expression at least in part through tran- 
scriptional control. The promoter region of human TGFB1 
gene is rich in G and C, contains 11 CCGCC repeats, 7 Spl 
binding sites, and has sequences similar to fat-specific ele- 
ment 2,  nuclear factor 1, and  12-tetradecanoyl-phorbol-13 
acetate responsive element, respectively, but contains nei- 
ther TATA nor CAAT boxes (Kim et al., 1989a).  TGFB1 has 
been shown to stimulate collagen gene expression by acting 
through the nuclear factor 1 site (Rossi et al.,  1988);  how- 
ever, TGFB1 enhancement of the expression of itself is not 
mediated through nuclear factor 1 site (Kim et al., 1989a,b), 
suggesting the presence of diverse pathways.  FGF induces 
diacylglycerol formation, protein kinase C  activation, and 
ionized calcium mobilization within minutes in Swiss 3T3 
cells (Tsuda et al.,  1985;  Kaibuchi et al.,  1986).  FGF was 
shown to enter the nucleolus and stimulate nucleolin produc- 
tion before the enhancement of ribosomal gene transcription 
in bovine aortic endothelial cells (Bouche et al., 1987).  The 
inhibition of the FGF effect by K252a suggests the involve- 
ment of  protein kinase activation in the mediation of the FGF 
effects on TFGB1 gene expression. Tumor promoter (12-tetro- 
decanoyl-phorbol-13  acetate) appears to activate the collagen- 
ase gene through pbosphorylation of  existing AP1 without de 
novo synthesis of the protein (Angel et al.,  1987).  Presence 
of the sequence similar to 12-tetradecanoyl-phorbol-13 ace- 
tate-responsive element in the promoter region of  the TGFB1 
gene (Kim et al., 1989a) suggests a similar mechanism in ac- 
tivation of TGFfll gene expression by FGE Additional studies 
are needed to identify the level(s)  where protein kinase(s) 
might be involved in mediation of FGF effects. 
FGF inhibits the expression of collagen and alkaline phos- 
phatase genes in rat osteoblasts or osteoblast-like cells (Canalis 
and Raisz,  1980;  Canalis et al.,  1987, 1988;  Rodan et al., 
1987, 1989) while it enhances the expression of osteocalcin 
in bovine bone cells (Globus et al., 1988) and osteopontilV2ar 
in mouse calvaria-derived MC3T3E1  (Noda,  M.,  unpub- 
lished data), rat osteosarcoma ROS17/2.8 cells (Rodan et al., 
1989),  and fibroblasts (Nomura et al., 1988).  FGF also ele- 
vates prostaglandin E2 production in cultured fetal calvaria 
(Canalis et al., 1987). These observations indicate that FGF 
enhances at least some of  the phenotypic expression of  osteo- 
blasts in certain conditions. TGFfl enhances the accumula- 
tion of extracellular matrix in many cells and tissues (Sporn 
et al.,  1987) and appears to possess features as an anabolic 
agent in bone metabolism both in vitro and in vivo (Canalis 
et al.,  1988b;  Centrella et al.,  1987a,b;  Noda and Rodan, 
1987; Noda et al., 1988a;  Noda and Camilliere, 1989). The 
results from this study suggest that FGF may act indirectly 
as an anabolic agent in bone via stimulation of  the expression 
of TGFfll gene. Alternatively, FGF enhancement of TGFfll 
expression may serve as  a  negative feedback mechanism 
against the inhibitory effects of FGF on osteoblastic pheno- 
types, such as alkaline phosphatase and collagen gene ex- 
pression. 
Both TGFfl and FGF are produced in and affect the func- 
tions of a wide variety of ceils. Whether the FGF effect on 
TGFfl expression might be found in cells other than osteo- 
blast-like cells and, if so, how general this FGF effect is still 
remain to be  answered by extensive screening of various 
types of cells. 
FGF- and TGF/3-1ike factors are involved in mesodermal 
induction from animal hemisphere in early Xenopus embryo- 
genesis (Kimelman and Kirschner, 1987; Weeks and Melton, 
1987; Rosa et al.,  1988),  indicating the coordinate relation- 
ship of FGF and TGFfl in vivo.  The physiological signifi- 
cance of FGF regulation of TGFfll gene expression in modu- 
lation of cellular function in local milieu in vivo remains to 
be determined. 
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